Instil Competitors
| TIL Stock | USD 7.42 0.33 4.65% |
Instil Bio vs Shattuck Labs Correlation
Pay attention - limited upside
The correlation between Instil Bio and STTK is -0.9 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Instil Bio and STTK in the same portfolio, assuming nothing else is changed.
Moving together with Instil Stock
Moving against Instil Stock
| 0.81 | DSGN | Design Therapeutics | PairCorr |
| 0.78 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.71 | ENGN | enGene Holdings Common | PairCorr |
| 0.6 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.6 | KYTX | Kyverna Therapeutics | PairCorr |
Instil Bio Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Instil Bio and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Instil and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Instil Bio does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Instil Stock performing well and Instil Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Instil Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ZNTL | 5.03 | 1.02 | 0.21 | 0.63 | 4.26 | 17.36 | 48.58 | |||
| SRZN | 4.41 | 0.94 | 0.19 | 0.82 | 4.44 | 13.34 | 34.29 | |||
| PLRX | 2.58 | (0.52) | 0.00 | (0.33) | 0.00 | 4.58 | 22.72 | |||
| ONCY | 3.90 | (0.37) | 0.00 | (0.12) | 0.00 | 8.55 | 27.46 | |||
| ATOS | 3.53 | (1.12) | 0.00 | 47.88 | 0.00 | 6.75 | 42.59 | |||
| WHWK | 3.46 | 0.40 | 0.11 | 0.38 | 3.47 | 6.98 | 21.49 | |||
| MGNX | 3.05 | 0.19 | 0.04 | 0.98 | 3.45 | 6.83 | 24.44 | |||
| TVGN | 4.80 | (1.13) | 0.00 | (0.36) | 0.00 | 10.00 | 26.81 | |||
| IFRX | 4.84 | (0.62) | 0.00 | (0.20) | 0.00 | 7.92 | 43.11 | |||
| STTK | 3.53 | 1.12 | 0.33 | 1.98 | 2.84 | 6.42 | 27.07 |
Cross Equities Net Income Analysis
Compare Instil Bio and related stocks such as Zentalis Pharmaceuticals, Surrozen, and Pliant Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZNTL | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (45.7 M) | (117.8 M) | (158.7 M) | (236.8 M) | (292.2 M) | (165.8 M) | (149.3 M) | (156.7 M) |
| SRZN | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (32.6 M) | (52.5 M) | (27.7 M) | (43 M) | (63.6 M) | (57.2 M) | (60.1 M) |
| PLRX | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (30.3 M) | (631 K) | (39.7 M) | (17.9 M) | (123.3 M) | (161.3 M) | (210.3 M) | (189.3 M) | (179.8 M) |
| ONCY | (574.5 K) | (29 M) | (36.4 M) | (23.5 M) | (18.6 M) | (13.7 M) | (15.1 M) | (15.6 M) | (17 M) | (45.6 M) | (16.8 M) | (21 M) | (19.1 M) | (20.6 M) | (31.7 M) | (28.5 M) | (27.1 M) |
| ATOS | (122.9 K) | (3.4 M) | (5.1 M) | (10.8 M) | (14.7 M) | (15.8 M) | (6.4 M) | (8.1 M) | (11.4 M) | (17.2 M) | (17.8 M) | (20.6 M) | (26.2 M) | (30.1 M) | (25.5 M) | (23 M) | (21.8 M) |
| WHWK | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (3.5 M) | (110.1 M) | (60.5 M) | (65.8 M) | (63.7 M) | (57.3 M) | (60.2 M) |
| MGNX | 6.7 M | 6.7 M | 8.4 M | (260.8 K) | (38.3 M) | (20.1 M) | (58.5 M) | (19.6 M) | (171.5 M) | (151.8 M) | (117.8 M) | (190.9 M) | (120 M) | (9.1 M) | (67 M) | (60.3 M) | (63.3 M) |
| TVGN | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | 4.4 M | (60.5 M) | (10.1 M) | (9.1 M) | (9.6 M) |
| IFRX | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (8.9 M) | (24.2 M) | (29.8 M) | (59.6 M) | (38.7 M) | (53.9 M) | (31 M) | (42.7 M) | (46.1 M) | (41.5 M) | (43.5 M) |
| STTK | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (24 M) | (35.4 M) | (45 M) | (100.6 M) | (87.3 M) | (75.4 M) | (67.9 M) | (71.3 M) |
Instil Bio and related stocks such as Zentalis Pharmaceuticals, Surrozen, and Pliant Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Instil Bio financial statement analysis. It represents the amount of money remaining after all of Instil Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Instil Bio Competitive Analysis
The better you understand Instil Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Instil Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Instil Bio's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Instil Bio Competition Performance Charts
Five steps to successful analysis of Instil Bio Competition
Instil Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Instil Bio in relation to its competition. Instil Bio's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Instil Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Instil Bio's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Instil Bio, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Instil Bio position
In addition to having Instil Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Blend Funds Thematic Idea Now
Small Blend Funds
Fund or Etfs that invest in stocks of small to mid-sized entities that have characteristics of both growth and value companies. The Small Blend Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Blend Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Instil Bio Correlation with its peers. For more information on how to buy Instil Stock please use our How to buy in Instil Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Instil Bio. If investors know Instil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Instil Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Instil Bio's market price often diverges from its book value, the accounting figure shown on Instil's balance sheet. Smart investors calculate Instil Bio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Instil Bio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Instil Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Instil Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Instil Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.